Last reviewed · How we verify
NCT07158294: DiP-in-CML
Identification of BCR::ABL1 Mutations by Digital PCR in CML
NA trial testing Peripheral blood withdrawal for BCR::ABL1 mutations testing in Chronic Myeloid Leukemia (CML) in 150 participants. Not yet recruiting.
1 February 2029
Quick facts
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 150 |
| Start date | 1 February 2026 |
| Primary completion | 1 February 2029 |
| Estimated completion | 1 April 2029 |
Drugs / interventions tested
- Peripheral blood withdrawal for BCR::ABL1 mutations testing
Conditions studied
- Chronic Myeloid Leukemia (CML) — all drugs for Chronic Myeloid Leukemia (CML) →
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto — full company profile →
Who can join
18 and older, any sex, with Chronic Myeloid Leukemia (CML). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to asses the ability of digital PCR (ddPCR) to detect actionable mutations in adult CML patients with failure of TKI therapy. The main objective of the study is it aims to answer is to assess whether ddPCR is at least as effective as NGS in detecting actionable (2GTKI-resistant) mutations. To accomplish this aim, samples of participants treated according to clinical practice, will be taken and analyzed for the presence of BCR::ABL1 KD mutations by ddPCR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07158294
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Myeloid Leukemia (CML)
Currently open trials in the same condition.
- NCT07165535 — Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network · recruiting
- NCT06514534 — Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligi · Phase 2 · recruiting
- NCT05589896 — A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantat · Phase 1, PHASE2 · recruiting
- NCT03849651 — TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-ce · Phase 2 · active not recruiting
- NCT03481868 — EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors · NA · recruiting
Other Gruppo Italiano Malattie EMatologiche dell'Adulto trials
Trials by the same sponsor.
- NCT07356960 — Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world · not yet recruiting
- NCT07249606 — Momelotinib Effectiveness in Myelofibrosis · not yet recruiting
- NCT06880601 — Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma · Phase 2 · not yet recruiting
- NCT06657846 — HRQoL and Financial Toxicity in Patients With VEXAS Syndrome · recruiting
- NCT05613296 — Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07158294 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Malattie EMatologiche dell'Adulto
- Last refreshed: 5 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07158294.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing